Niagen Bioscience Q2 net sales fall, missing estimates

Niagen Bioscience

04/08/2026 21:09

Overview
U.S. bioscience firm's Q2 net sales declined and missed analyst expectations
Q2 net income was $1.0 mln, down from $3.6 mln a year earlier
Company launched pharmaceutical program for rare diseases and at-home telehealth platform

Outlook
Company expects 2026 e-commerce business to grow 10% to 15% year-over-year
Ingredient business expected to be lower than prior year due to competitive market
Company anticipates higher 2026 operating expenses as it invests in strategic priorities

Result Drivers
DIRECT-TO-CONSUMER GROWTH - Co said direct-to-consumer sales on its website grew 23% year-over-year, led by Tru Niagen
NEW BUSINESS INITIATIVES - Co launched Niagen Plus telehealth platform and pharmaceutical program targeting rare genetic diseases and aging disorders

Company press release: ID:nBw6D3vsJa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
Miss
$29.79 mln
$30.69 mln (6 Analysts)
Q2 Net Income
 
$963,000
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Niagen Bioscience Inc is $11.00, about 211.6% above its August 3 closing price of $3.53
The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 17 three months ago

Reuters Recommended Reads
Aug 4 - Lipocine Q2 net loss widens as revenue declines
Aug 4 - Palvella Therapeutics Q2 net loss widens on higher expenses
Aug 3 - Stoke Therapeutics Q2 revenue falls 33% on lower collaboration, licensing income

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)